Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications

NCT04374487 is registered in ClinicalTrials.gov with Max Healthcare Insititute Limited as lead sponsor.

NCT NCT04374487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04374487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
Lead sponsor
Max Healthcare Insititute Limited
Phase
Phase 2
Overall status
Unknown status
Start date
May 9, 2020
Completion date
August 9, 2021
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19